Fresenius Medical Care AG & Co. KGaA(FMS) Stock Research - Grey Stern Research
Loading...

Fresenius Medical Care AG & Co. KGaA (FMS) Stock Analysis

$21.97 (0.98%)

FMS Financial Performance


Use the table below to view Fresenius Medical Care AG & Co. KGaA's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q4 - 2023

Metric Value Ranking among Peers
Price $22.39 -
52 Week Low $16.37 -
52 Week High $27.72 -
Market Cap $13.1 Billion 2/13
Gross Margin 27% 5/13
Profit Margin 4% 9/13
EBITDA margin 18% 3/13
Q4 - 2023 Revenue $5.5 Billion 2/13
Q4 - 2023 Earnings $206.5 Million 4/13
Q4 - 2023 Free Cash Flow $515.2 Million 3/13
Trailing 4 Quarters Revenue $21.4 Billion 2/13
Trailing 4 Quarters Earnings $600.5 Million 4/13
Quarterly Earnings Growth -3% 11/13
Annual Earnings Growth -38% 12/13
Quarterly Revenue Growth 0% 12/13
Annual Revenue Growth -4% 13/13
Cash On Hand $1.5 Billion 1/13
Short Term Debt $1.7 Billion 2/13
Long Term Debt $11.5 Billion 3/13

Fresenius Medical Care AG & Co. KGaA Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Fresenius Medical Care AG & Co. KGaA's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 21.88 6/13
PS 0.56 13/13
PB 0.81 12/13
PC 8.52 11/13
Liabilities to Equity 1.40 8/13
ROA 0.02 7/13
ROE 0.04 8/13
Current Ratio 1.78 5/13
Quick Ratio 0.08 4/13
Long Term Debt to Equity 0.77 8/13
Debt to Equity 0.88 8/13
Burn Rate 2.33 5/13
Cash to Cap 0.12 2/13
CCR 2.49 2/13
EV to EBITDA 28.49 10/13
EV to Revenue 1.17 10/13

Company Details

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

CEO: Mr. Robert Maurice Powell Jr.

Website: https://www.freseniusmedicalcare.com

Address: Else-Kroner Strasse 1 Bad Homburg,

Exchange: New York Stock Exchange

Industry: Medical Care Facilities

Fresenius Medical Care AG & Co. KGaA Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Fresenius Medical Care AG & Co. KGaA. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Tenet Healthcare Corporation THC $12.5 Billion
HCA Healthcare, Inc. HCA $84.6 Billion
Universal Health Services, Inc. UHS $10.6 Billion
Acadia Healthcare Company, Inc. ACHC $6.2 Billion
Surgery Partners, Inc. SGRY $3.3 Billion
Select Medical Holdings Corporation SEM $4.4 Billion
Encompass Health Corporation EHC $8.6 Billion
Addus HomeCare Corporation ADUS $1.8 Billion
The Ensign Group, Inc. ENSG $6.8 Billion
Aesthetic Medical International Holdings Group Limited AIH $23.8 Million
The Pennant Group, Inc. PNTG $691.7 Million
InnovAge Holding Corp. INNV $503.2 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
FMS Income Statements
Quarter Year Revenue Earnings
Q4 2023 € 5.0 Billion €187.9 Million
Q3 2023 € 4.9 Billion €84.4 Million
Q2 2023 € 4.8 Billion €140.4 Million
Q1 2023 € 4.7 Billion €133.9 Million
Q4 2022 € 5.0 Billion €194.0 Million
Q3 2022 € 5.1 Billion €230.1 Million
Q2 2022 € 4.8 Billion €147.0 Million
Q1 2022 € 4.5 Billion €157.4 Million

View All

FMS Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2023 €1.4 Billion €33.9 Billion €12.1 Billion €14.8 Billion
Q3 2023 €1.6 Billion €35.6 Billion €13.0 Billion €15.4 Billion
Q2 2023 €1.4 Billion €35.0 Billion €13.1 Billion €13.5 Billion
Q1 2023 €1.2 Billion €35.5 Billion €13.3 Billion €13.8 Billion
Q4 2022 €1.3 Billion €35.8 Billion €13.2 Billion €15.4 Billion
Q3 2022 €1.1 Billion €38.4 Billion €13.8 Billion €16.7 Billion
Q2 2022 €0 €36.1 Billion €13.7 Billion €15.5 Billion
Q1 2022 €1.2 Billion €34.7 Billion €13.3 Billion €14.5 Billion

View All

FMS Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q4 2023 €468.8 Million -€250.3 Million -€126.0 Million
Q3 2023 €623.0 Million -€136.8 Million €213.1 Million
Q2 2023 €851.7 Million -€155.4 Million €137.4 Million
Q1 2023 €704,000 -€142.1 Million -€49.9 Million
Q4 2022 €169.0 Million -€431.0 Million €160.2 Million
Q3 2022 €497.3 Million -€160.3 Million €88.9 Million
Q2 2022 €410.0 Million -€341.0 Million €0
Q1 2022 -€3.4 Million -€162.1 Million -€308.3 Million

View All